NHS to approve new drug Hiprex for recurrent UTIs starting December 12

A new drug, methenamine hippurate, known as Hiprex, is set to be approved for NHS use starting December 12. This drug will provide a more affordable option for patients with recurrent urinary tract infections (UTIs), who currently pay over £500 annually for private prescriptions. The updated guidelines from the National Institute for Health and Care Excellence (NICE) will allow general practitioners to prescribe Hiprex as an alternative to long-term antibiotics. This change aims to improve access for patients suffering from recurrent UTIs, although official guidance for chronic UTIs remains absent. Previously, Hiprex was available over the counter but became prescription-only, limiting access. The new guidelines are expected to increase prescriptions, making it easier for patients to obtain the drug through the NHS rather than relying on private care.